The ADHD Medication Shortage: What Every Patient and Physician Needs to Know Right Now

Author: R. Murray

Date: March 26, 2026

Category: Family Health, Physician Wellness, Mental Health

Tags: ADHD, medication shortage, stimulants, Adderall, physician burnout, mental health

I had a 34-year-old woman in my office last month who had been properly diagnosed with ADHD at age 31.... finally, after three decades of being told she was "disorganized," "scattered," or "just anxious." She'd worked hard to get that diagnosis. She'd found a medication that worked. And then, for the fourth month in a row, her pharmacy couldn't fill her prescription.

She sat across from me with a look I've come to recognize too well: exhausted, embarrassed, and quietly furious. Not at me, but at a system that finally saw her.... and then couldn't actually help her.

That look is what's motivating me to write this post today. Because the ADHD medication shortage is not a supply chain blip that's about to resolve itself. It is a structural problem with multiple causes, and it is affecting millions of people right now in ways that are genuinely harmful.

The Scale of What's Happening

Let me give you some numbers, because I think they help put the human stories in context.

Approximately one third of U.S. adults with ADHD took stimulant medication in the past year. Of those who tried to fill their prescriptions, 71.5% reported difficulty getting their medication because it was unavailable. That is not a small inconvenience. That is the majority of people on these medications hitting a wall.

And the patients who are most affected are often those who most need consistency.... adults who finally found something that lets them hold a job, parent effectively, maintain relationships, and manage their lives. Interrupting that medication unexpectedly doesn't just cause inconvenience. It can mean lost jobs, failed coursework, fractured family dynamics, and worsened mental health across the board.

Why Is This Happening?

The shortage has several intersecting causes, and honestly, none of them are easy to fix quickly.

DEA production quotas. Stimulant medications like amphetamine salts (Adderall) and methylphenidate (Ritalin, Concerta) are classified as Schedule II controlled substances. The DEA sets annual manufacturing quotas for these drugs, and increasing those quotas requires a lengthy regulatory process. As demand has grown faster than anticipated, the supply ceiling hasn't kept pace.

Dramatically increased demand. The awareness of ADHD.... especially in adults, and especially in women.... has expanded significantly over the past several years. Telehealth made diagnosis more accessible. Social media helped many people recognize themselves in descriptions of ADHD they'd never encountered before. The result has been a genuine, legitimate surge in people seeking evaluation and treatment.... a surge that the medication supply was not built to absorb.

Overdiagnosis concerns. This is the more uncomfortable part of the conversation. Some researchers and clinicians are raising valid concerns that a subset of new ADHD diagnoses.... particularly those made via rapid telehealth visits without thorough neuropsychological assessment.... may not meet rigorous diagnostic criteria. One American Journal of Managed Care analysis argued that overdiagnosis of adult ADHD is directly exacerbating the stimulant shortage by expanding the pool of prescriptions beyond what the supply chain can support. This doesn't mean ADHD is overdiagnosed across the board. But it does mean the diagnostic process matters.... a lot.

Physician training gaps. Here is something that genuinely concerns me professionally: only 45% of physicians and nurse practitioners can correctly answer questions about adult ADHD prevalence, risk factors, comorbidities, and impact. Only 41% correctly identify diagnostic criteria and know about screening tools. Two-thirds of providers who treat adults with ADHD report feeling ill-equipped to do so. These are not comfortable statistics for our field to sit with.

What This Looks Like on the Ground

If you are a patient currently trying to navigate this shortage, here is what I want you to know.

First, you are not doing anything wrong, and this is not your fault. The frustration of calling five pharmacies every month, being put on waiting lists, or being told that your medication simply isn't available is a real and legitimate burden. It is a system failure, not a personal one.

Second, your options are not as limited as they may feel in the moment. Talk to your prescribing physician about whether an alternative formulation or a different stimulant medication might be available and appropriate for you. Extended-release and immediate-release versions sometimes have different availability profiles. Generic vs. brand can also matter. Different pharmacies.... including some smaller independent pharmacies.... may have stock that larger chains do not.

Third, if stimulants are unavailable, there are non-stimulant options for ADHD that are worth discussing with your doctor. Strattera (atomoxetine), Qelbree (viloxazine), Intuniv (guanfacine), and Kapvay (clonidine) are all FDA-approved for ADHD and are not subject to the same scheduling constraints. They work differently and aren't right for everyone, but they are genuinely viable for some patients.

What This Looks Like for Physicians

For those of us on the prescribing side, this shortage has created a set of challenges I want to name directly.

Managing ADHD in an era of shortage means more follow-up calls, more creative problem-solving around formulations, more time spent on prior authorizations and pharmacy coordination. That's time most of us don't have in abundance. It also means harder conversations with patients who are struggling and looking to us for solutions we sometimes cannot provide.

I've also had to examine my own diagnostic practices more carefully. Not because I doubt the patients I've diagnosed, but because the stakes of accurate diagnosis have become higher. An ADHD diagnosis today has supply chain implications that it didn't have five years ago. That's a strange new reality, and it demands rigor.

For physicians who feel underprepared: CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder) and the American Professional Society of ADHD and Related Disorders (APSARD) both offer CME resources on adult ADHD diagnosis and management that I've found genuinely useful.

What I'm Doing Differently in My Practice

A few practical changes I've made:

I now build medication availability checks into my prescribing workflow.... before writing, I'm more likely to call ahead or have my team check local pharmacy stock for common stimulant formulations.

I'm having earlier conversations about non-stimulant alternatives as genuine first-line options for some patients, not just backup plans.

I'm making sure patients understand that calling my office when they hit a shortage is the right move, not something to handle alone. We can help troubleshoot.

And I'm being explicit with patients that the shortage is not a signal that their diagnosis is wrong or that treatment isn't available. It's a supply problem, not a legitimacy problem.

The Larger Picture

The ADHD medication shortage is, in some ways, a symptom of a broader pattern: healthcare infrastructure that struggles to adapt quickly to genuine shifts in population health needs. ADHD is not new. The recognition of it across the lifespan.... in adults, in women, in people who compensated for decades before seeking help.... is newer. And the system hasn't caught up.

I don't have a tidy resolution to offer. But I do believe that informed patients and informed physicians, working together and communicating clearly, can navigate this better than either can alone.

If you're struggling to access your ADHD medication right now, please reach out to your prescribing physician. Bring your pharmacy information, be open to discussing alternatives, and know that the conversation is worth having.

Stay Connected

Enjoy these posts? Get new articles from R. Murray delivered to your inbox.

Subscribe to My Medical Journal

This post reflects my personal experience and is for informational purposes only. It is not medical advice. Please consult your own physician before making any health decisions.